ORNBV.HE
Latest Trade
40.32EURChange
-0.21(-0.52%)Volume
326,418Today's Range
-
40.5652 Week Range
-
40.96As of on the Helsinki Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 40.53 |
|---|---|
Open | 40.52 |
Volume | 326,418 |
3M AVG Volume | 7.11 |
Today's High | 40.56 |
Today's Low | 40.02 |
52 Week High | 40.96 |
52 Week Low | 28.19 |
Shares Out (MIL) | 140.49 |
Market Cap (MIL) | 5,670.59 |
Forward P/E | 28.29 |
Dividend (Yield %) | -- |
Orion Group Q3 Operating Profit Up At EUR 90.7 Mln
Orion To Withdraw Melatoniini Orion Spray
Oriola And Orion Renew Their Distribution Agreement
Orion Oyj is a Finland-based company engaged in the development, manufacture and marketing of pharmaceuticals and diagnostic tests. The Company operates, along with its subsidiaries, in two business segments: the Pharmaceuticals business segment develops, manufactures and markets pharmaceuticals and active pharmaceutical ingredients, and the Diagnostics business segment develops, manufactures and markets diagnostic tests. The Company’s business comprises two main divisions: Proprietary Products and Specialty Products. Its Proprietary Products consist of patented prescription products in three therapy areas: central nervous system diseases, oncology and critical care, and Easyhaler pulmonary drugs. The Company’s Specialty Products, which include the provision of generic prescription drugs and self-care products for basic healthcare. In addition the Company also produces veterinary medicines for pets and production animals.
Industry
Biotechnology & Drugs
Executive Leadership
Heikki Westerlund
Independent Chairman of the Board
Timo Lappalainen
President, Chief Executive Officer, Chairman of the Executive Management Board
Timo Maasilta
Independent Vice Chairman of the Board
Jari Karlson
Chief Financial Officer; Senior Vice President, Animal Health; Member of the Executive Management Board
Satu Ahomaki
Senior Vice President, Commercial Operations; Member of the Executive Management Board
Price To Earnings (TTM) | 27.11 |
|---|---|
Price To Sales (TTM) | 5.46 |
Price To Book (MRQ) | 7.95 |
Price To Cash Flow (TTM) | 21.71 |
Total Debt To Equity (MRQ) | 1.15 |
LT Debt To Equity (MRQ) | 0.72 |
Return on Investment (TTM) | 26.59 |
Return on Equity (TTM) | 20.68 |
* ANNOUNCES COMPLETION OF ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) FOR DAROLUTAMIDE TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA)
* REG-ORION TO SELL ITS ORION DIAGNOSTICA DIVISION - DUE TO THE TRANSACTION ORION UPDATES ITS OUTLOOK
* STATUS UPDATE OF THE PHASE III ARAMIS CLINICAL TRIAL WITH DAROLUTAMIDE IN PATIENTS WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
* ORION HAS RECEIVED POSITIVE CONCLUSIONS FOR THE SALMETEROL-FLUTICASONE EASYHALER® COMBINATION UNDER THE EU'S DECENTRALIZED PROCEDURES
* 17 PERSONS OF COMPANY'S PERSONNEL WILL BE GIVEN A NOTICE.
* ESTIMATES THAT IN 2018 NET SALES WILL BE AT SAME LEVEL OR SLIGHTLY LOWER THAN IN 2017
* REG-ORION TO INVESTIGATE POSSIBLE SALE OF ORION DIAGNOSTICA Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Iraq agreed a deal with U.S. energy company Orion on Monday to process natural gas extracted at its giant Nahr Bin Omar oilfield.
IRAQ SIGNS AGREEMENT WITH U.S. FIRM ORION TO PROCESS GAS FROM NAHR BIN OMAR OILFIELD - IRAQI OIL MINISTRY
* COMPANY WILL LAUNCH CO-OPERATION NEGOTIATIONS IN LABORATORY OPERATIONS
* Q3 SALES EUR 252.7 MILLION (REUTERS POLL EUR 266 MILLION)
* Revival Gold Inc closes $9 million private placement and announces strategic relationship with Orion Mine Finance
* Osisko Gold Royalties Ltd - shareholders have approved at 99.6% issuance of shares required to complete acquisition of Orion portfolio
* Q4 sales 279.9 million euros ($298.18 million) versus 273 million euros seen in Reuters poll
* Says Government Of Singapore has acquired 302,186 shares of the company, increasing its stake in the cpmpany up to 5.0 percent from 0 percent
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.